These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 24769349)

  • 1. Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach.
    Li X; Chen W; Tian Y; Liu H; Zhan P; De Clercq E; Pannecouque C; Balzarini J; Liu X
    Eur J Med Chem; 2014 Jun; 80():112-21. PubMed ID: 24769349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach.
    Wang L; Tian Y; Chen W; Liu H; Zhan P; Li D; Liu H; De Clercq E; Pannecouque C; Liu X
    Eur J Med Chem; 2014 Oct; 85():293-303. PubMed ID: 25089812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Wu HQ; Yao J; He QQ; Chen WX; Chen FE; Pannecouque C; De Clercq E; Daelemans D
    Bioorg Med Chem; 2015 Feb; 23(3):624-31. PubMed ID: 25537532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
    Chen W; Zhan P; Daelemans D; Yang J; Huang B; De Clercq E; Pannecouque C; Liu X
    Eur J Med Chem; 2016 Oct; 121():352-363. PubMed ID: 27267005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored "hydrophobic channel".
    Zhou Z; Liu T; Kang D; Huo Z; Wu G; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    Org Biomol Chem; 2018 Feb; 16(6):1014-1028. PubMed ID: 29349445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
    Lu X; Yang J; Kang D; Gao P; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    Bioorg Med Chem; 2018 May; 26(8):2051-2060. PubMed ID: 29559197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
    Huang B; Liang X; Li C; Chen W; Liu T; Li X; Sun Y; Fu L; Liu H; De Clercq E; Pannecouque C; Zhan P; Liu X
    Eur J Med Chem; 2015 Mar; 93():330-7. PubMed ID: 25707013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
    Wu HQ; Yan ZH; Chen WX; He QQ; Chen FE; De Clercq E; Balzarini J; Daelemans D; Pannecouque C
    Bioorg Med Chem; 2013 Nov; 21(21):6477-83. PubMed ID: 24055077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.
    Wang J; Zhan P; Li Z; Liu H; De Clercq E; Pannecouque C; Liu X
    Eur J Med Chem; 2014 Apr; 76():531-8. PubMed ID: 24602795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus.
    Zhou Z; Liu T; Wu G; Kang D; Fu Z; Wang Z; De Clercq E; Pannecouque C; Zhan P; Liu X
    Org Biomol Chem; 2019 Mar; 17(12):3202-3217. PubMed ID: 30839042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
    Rai D; Chen W; Tian Y; Chen X; Zhan P; De Clercq E; Pannecouque C; Balzarini J; Liu X
    Bioorg Med Chem; 2013 Dec; 21(23):7398-405. PubMed ID: 24134904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Chen X; Liu X; Meng Q; Wang D; Liu H; De Clercq E; Pannecouque C; Balzarini J; Liu X
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6593-7. PubMed ID: 24239481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
    Meng G; Liu Y; Zheng A; Chen F; Chen W; De Clercq E; Pannecouque C; Balzarini J
    Eur J Med Chem; 2014 Jul; 82():600-11. PubMed ID: 24952305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
    Meng Q; Chen X; Kang D; Huang B; Li W; Zhan P; Daelemans D; De Clercq E; Pannecouque C; Liu X
    Eur J Med Chem; 2016 Jun; 115():53-62. PubMed ID: 26994843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
    Liu Z; Chen W; Zhan P; De Clercq E; Pannecouque C; Liu X
    Eur J Med Chem; 2014 Nov; 87():52-62. PubMed ID: 25240095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
    Jin K; Yin H; De Clercq E; Pannecouque C; Meng G; Chen F
    Eur J Med Chem; 2018 Feb; 145():726-734. PubMed ID: 29353724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors.
    Ribone SR; Leen V; Madrid M; Dehaen W; Daelemans D; Pannecouque C; Briñón MC
    Eur J Med Chem; 2012 Dec; 58():485-92. PubMed ID: 23159806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
    Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
    Yang J; Chen W; Kang D; Lu X; Li X; Liu Z; Huang B; Daelemans D; Pannecouque C; De Clercq E; Zhan P; Liu X
    Eur J Med Chem; 2016 Feb; 109():294-304. PubMed ID: 26802545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
    Gu SX; Yang SQ; He QQ; Ma XD; Chen FE; Dai HF; Clercq ED; Balzarini J; Pannecouque C
    Bioorg Med Chem; 2011 Dec; 19(23):7093-9. PubMed ID: 22037050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.